Latest news

• Boehringer pulls faldaprevir and exits hepatitis C market

  After a strategic review of its business, the company said it had elected to withdraw all regulatory filings for faldaprevir - a protease inhibitor - because the "HCV treatment environment has significantly and ... Faldaprevir was always likely to be at

• Boehringer's faldaprevir set for rapid review in Europe

  Boehringer's marketing application is largely based on the results of the STARTverso studies, which compared faldaprevir or placebo on top of interferon and ribavirin therapy. ... Meanwhile, faldaprevir is also in pivotal trials as part of an

• J&J wins FDA panel backing for hepatitis C drug

  Other drugs emerging in the protease inhibitor class include Boehringer Ingelheim's faldaprevir, Merck's vaniprevir, Bristol-Myers Squibb's asunaprevir and AbbVie's ABT 450, which also claim superior viral

• Boehringer says faldaprevir does well in Asian hepatitis C patients

  That is significant because some patients with hepatitis C virus also have HIV, and as a result Boehringer has included co-infected patients in its faldaprevir trials programme. ... Boehringer recently started pivotal trials of an interferon-free

• Boehringer launches online education portal for hepatitis C

  The launch of the US-focused HepCRedefined.com site came on the day the pharma company moved its interferon-free hep C regimen, which combines faldaprevir and BI 207127, into phase